Beyond Weight Loss
New Research Reveals Evolving Understanding of Weight-Loss Drugs' Health Benefits and Challenges
Anonymous
Drugs like Ozempic and Wegovy have gone from diabetes treatments to something far bigger. As of mid-2026, roughly 12% of U.S. adults use these medications — up from 5.8% in 2024 — according to Gallup. The FDA has now approved them for heart attack prevention, sleep apnea, kidney disease, and severe liver disease, and researchers are still finding new uses.
The science is moving fast. A global GLP-1 drug market projected to hit $200 billion by 2030, according to J.P. Morgan, is reshaping medicine, food, and insurance all at once. What doctors and patients thought they knew about these drugs just two years ago is already out of date.
Far More Than a Weight-Loss Pill Now
These drugs started as diabetes treatments. Ozempic got FDA approval in 2017. Wegovy followed in 2021 for obesity. But the list of approved uses has grown sharply since then. In March 2024, the FDA approved Wegovy to cut the risk of heart attacks and strokes. By June 2024, Zepbound was cleared for sleep apnea. In August 2025, Wegovy got the green light for a serious liver disease called MASH, according to Star-Telegram.
Researchers now believe these drugs may protect organs in ways that go beyond weight loss. The leading theory is that they directly reduce inflammation in blood vessels and organs. That could explain why patients see improvements in kidney function and heart health even before they lose significant weight, according to Charlotte Observer.
Addiction and Long COVID Are the Next Frontiers
Scientists at Washington University found that GLP-1 drugs cut the risk of opioid, alcohol, and cannabis use disorders. The drugs appear to target the same brain pathways involved in addiction. The results were published in a 2026 BMJ study led by Dr. Ziyad Al-Aly, according to Bellingham Herald.
Researchers at Scripps Research are running a clinical trial using tirzepatide — the drug in Zepbound — for Long COVID. The study, called LoCITT-T, is targeting symptoms like fatigue and brain fog. If it works, the implications could be enormous. Tens of millions of people worldwide still struggle with Long COVID symptoms, according to Kentucky.com.
Stopping the Drug Often Means Regaining the Weight
One of the biggest challenges is what happens when people stop. About 25% of patients regain all the weight they lost within 24 months of quitting, according to Epic Research. Another problem: patients often regain fat but not muscle. University of Pennsylvania researchers call this dangerous because it shifts body composition and makes future weight loss harder, according to Island Packet.
Still, 56% of patients do sustain some weight loss after stopping. And results while on the drugs are striking. Patients on Zepbound lost an average of 48 pounds — about 22.5% of their body weight — over 72 weeks in clinical trials. The key debate now is whether people need to stay on these drugs for life, the way someone with high blood pressure takes a daily pill, according to Myrtle Beach Online.
Side Effects, Costs, and a Reshaping Economy
The drugs are not without downsides. About 9 to 10% of users report "Ozempic breath" — a sulfur or metallic taste caused by slow digestion — and "Ozempic face," which is fat loss from the cheeks and jaw. Nausea, vomiting, and diarrhea are common early on. Muscle loss is also a real risk; experts recommend strength training and eating at least 100 grams of protein daily to counter it, according to Tri-City Herald.
Cost is a huge barrier. Medicaid spending on these drugs jumped from $1 billion in 2019 to $8.6 billion in 2024, according to KFF. Starting July 1, 2026, a new Medicare program will cap copays at $50 per month for eligible seniors. Meanwhile, the food industry is bracing for disruption — estimates suggest 1 million fewer truckloads of food will move annually in the U.S. by 2031 as people simply eat less, according to Ledger-Enquirer.
Sentiment
NeutralNEGATIVENEUTRALPOSITIVE
Publishers
9
Articles
9
Reach
9
Topics
A
AnonymousAuthor
